Primary Sclerosing Cholangitis (PSC) is a progressive disease of the biliary system which might lead to increased risk of cholangiocancer. PSC constitutes a common indication for adult liver transplantation (ltx). In 80% of cases PSC is associated with inflammatory bowel disease (IBD), while 3-5 % of patients with colonic IBD, suffer from the disease. The conservative treatment options are few. There is a relatively high risk of recurrency after ltx.
Conditions
Interventions
Trade Name: Vancomycin
Product Name: vancomycin
Pharmaceutical Form: Capsule
Trade Name: vancomycin
Product Name: Vancomycin
Pharmaceutical Form: Oral solution
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children and adolescents > 1 year =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Known hypersensitivity towards vancomycin Pregnancy Chronic renal failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To study if oral vancomycin during 1 year may improve liver- and gut function. ;Secondary Objective: To study if oral vancomycin during 1 year may improve liver histology and magnetic resonance cholangiography (MRC);Primary end point(s): Clinical status of patients after 1 year Improvement of symptoms after 1 year Improvement of liver function tests after 1 year Improvement of bile duct stenosis as measured by MRC after 1 year Improvement of liver histology after 1 year;Timepoint(s) of evaluation of this end point: One year after treatment start | — |
Countries
Sweden
Outcome results
None listed